Across 887 European oncology Phase III CTIS trial records from 2024–2026, CRO or specialist provider support appeared in 443 trials, equal to 49.9%. IQVIA was the most active provider, appearing in 163 trials, followed by ICON/PRA in 127, Clario/Bioclinica/ERT in 125, PPD/Thermo Fisher in 121, and Parexel in 118. CRO need was strongest in operationally large EU submissions: 169 of 187 trials with at least 10 countries used CRO support, and 194 of 251 trials with at least 50 sites used CRO support.
IQVIA led the cohort, supporting 163 of 887 trials, or 18.4% of all oncology Phase III trials and 36.8% of CRO-supported trials. The next cluster was tightly grouped: ICON/PRA supported 127 trials, Clario/Bioclinica/ERT 125, PPD/Thermo Fisher 121, and Parexel 118.
The CRO market signal is concentrated but not monopolized. IQVIA is the clear leader, while ICON/PRA, PPD/Thermo Fisher, Parexel, and Clario/Bioclinica/ERT form a second tier that each appear in more than one quarter of CRO-supported trials.
CRO use rose sharply with EU country and site complexity. Only 14 of 237 single-country trials used CRO support, equal to 5.9%, while 169 of 187 trials with at least 10 countries used CRO support, equal to 90.4%. Site footprint showed the same pattern: 194 of 251 trials with at least 50 sites used CRO support, equal to 77.3%.
The strongest CRO trigger is not sample size alone; it is EU execution complexity. Once a CTIS submission expands beyond five countries or approaches 50 sites, CRO support becomes the dominant operating model.
By absolute CRO-supported trial count, lung cancer led with 89 of 138 trials using CRO support, equal to 64.5%. Breast cancer followed with 61 of 125 trials, lymphoma/CLL with 39 of 63, multiple myeloma with 34 of 57, and prostate cancer with 30 of 62. Among indications with at least 10 trials, the highest CRO-use rates were endometrial/uterine cancer at 66.7%, bladder/urothelial cancer at 65.7%, and lung cancer at 64.5%.
| Indication group | CRO-supported | Total | Rate |
|---|---|---|---|
| Lung cancer | 89 | 138 | 64.5% |
| Breast cancer | 61 | 125 | 48.8% |
| Lymphoma / CLL | 39 | 63 | 61.9% |
| Multiple myeloma | 34 | 57 | 59.6% |
| Prostate cancer | 30 | 62 | 48.4% |
| Leukaemia / CLL | 26 | 48 | 54.2% |
| Bladder / urothelial cancer | 23 | 35 | 65.7% |
| Ovarian / fallopian / peritoneal cancer | 15 | 29 | 51.7% |
Lung cancer is the most attractive high-volume CRO demand pool because it combines scale with a high outsourcing rate. Bladder/urothelial and endometrial/uterine cancer show stronger relative CRO dependence, but on smaller Phase III trial bases.
The most common outsourced function was central lab, biomarker, and sample services, present in 439 of 887 trials, or 49.5%. CRO/site management/sponsor-duty support appeared in 420 trials, central imaging or blinded review in 260, electronic data capture/data management in 205, and patient services or reimbursement in 169.
Outsourcing is not limited to full-service CRO work. Phase III oncology trials most often outsource lab/biomarker operations, imaging review, trial systems, patient reimbursement, IRT, and IMP logistics, which reflects the operational burden of biomarker-driven and imaging-heavy oncology development.
CRO-supported trials had a median of 8 countries and 49 sites, compared with 1 country and 16 sites for trials without CRO support. The median time from initial CTIS submission to first CTIS authorization was 101 days in CRO-supported trials versus 56 days in non-CRO trials, consistent with larger and more complex multinational dossiers.
| Metric | CRO-supported | No CRO listed |
|---|---|---|
| Median EU/EEA countries | 8 | 1 |
| Median sites | 49 | 16 |
| Median planned sample size | 332 | 255 |
| Median recruitment window | 71 months | 68.5 months |
| Median initial CTIS submission to first authorization | 101 days | 56 days |
| Median listed third parties | 9 | 0 |
CRO-supported trials look like complex CTIS/EU submissions: broader country footprint, larger site networks, more third parties, and longer authorization timelines. CRO need is therefore best framed around submission orchestration and Part II country execution, not only patient enrollment.
Spain appeared in 368 of 443 CRO-supported trials, equal to 83.1%, making it the most frequent country footprint. Italy appeared in 338 trials, France in 330, Germany in 315, and Poland in 295. These countries also carried large site loads, including 3,606 sites in Spain, 3,025 in France, 2,920 in Italy, and 2,632 in Germany across CRO-supported trials.
| Country | Trials | Share of CRO trials | Sites |
|---|---|---|---|
| Spain | 368 | 83.1% | 3,606 |
| Italy | 338 | 76.3% | 2,920 |
| France | 330 | 74.5% | 3,025 |
| Germany | 315 | 71.1% | 2,632 |
| Poland | 295 | 66.6% | 1,488 |
| Belgium | 256 | 57.8% | 990 |
For CTIS Part II and country-level execution, the highest CRO workload is concentrated in Spain, Italy, France, Germany, and Poland. These markets combine frequent inclusion with large oncology site networks.
Pharmaceutical-company sponsors used CRO support in 413 of 570 trials, equal to 72.5%, compared with 10 of 201 hospital/clinic-sponsored trials, equal to 5.0%. Orphan-designated trials also had higher CRO use: 91 of 114 orphan-drug trials used CRO support, equal to 79.8%, versus 352 of 773 non-orphan trials, equal to 45.5%.
The strongest adjacent CRO-demand signal is a commercial sponsor plus complex modality or orphan-drug context. ADC and bispecific antibody Phase III trials show especially high CRO-use rates, likely because they combine complex safety, biomarker, supply, and multinational execution requirements.
The most active CRO/service-provider cluster in European oncology Phase III trials is led by IQVIA with 163 trial appearances, followed by ICON/PRA with 127, Clario/Bioclinica/ERT with 125, PPD/Thermo Fisher with 121, and Parexel with 118. CROs are needed most in trials crossing at least 10 EU/EEA countries, at least 50 sites, pharmaceutical-company sponsorship, orphan-drug status, ADC or bispecific modalities, and high-volume indications such as lung cancer, breast cancer, lymphoma/CLL, multiple myeloma, and prostate cancer.
CTIS means Clinical Trials Information System. EU/EEA country footprint refers to countries listed in the CTIS geography data. CRO means contract research organization; in this report, CRO support includes CROs and specialist service providers explicitly listed under CRO or third-party support fields.